Improved Anti-Treg Vaccination Targeting Foxp3 Efficiently Decreases Regulatory T Cells in Mice

被引:0
作者
Niri, Neda Mousavi [1 ]
Memarnejadian, Arash [2 ]
Pilehvar-Soltanahmadi, Younes [1 ]
Sadeghi, Mohammadreza Agha [2 ]
Mahdavi, Mehdi [3 ]
Kheshtchin, Nasim [4 ]
Arab, Samaneh [5 ]
Namdar, Afshin [7 ]
Jadidi, Farhad [6 ]
Zarghami, Nosratollah [1 ]
Hajati, Jamshid [4 ]
机构
[1] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Med Biotechnol, Tabriz 5154853431, Iran
[2] Pasteur Inst Iran, Dept Hepatitis & AIDS, Tehran, Iran
[3] Pasteur Inst Iran, Dept Immunol, Tehran, Iran
[4] Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran, Iran
[5] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Mol Med, Tehran, Iran
[6] Univ Tehran Med Sci, Sch Publ Hlth, Dept Immunol, Tehran, Iran
[7] Isfahan Univ Med Sci, Sch Med, Dept Immunol, Esfahan, Iran
基金
美国国家科学基金会;
关键词
regulatory; FOXP3; fragment c(IgG); vaccination; TRANSCRIPTION FACTOR FOXP3; CANCER-IMMUNOTHERAPY; METASTATIC MELANOMA; IMMUNE-RESPONSES; PERIPHERAL-BLOOD; FUSION PROTEIN; TUMOR-IMMUNITY; IN-VIVO; DEPLETION; CARCINOMA;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: The critical role of regulatory T (Treg) cells in dampening immune responses against tumor cells is apparent. Therefore, several methods have been introduced for eliminating Treg. Among them, inducing immune responses against Treg cells expressing Foxp3 transcription factor is a hopeful approach to decrease the frequency of Tregs. In current study, we used the chimeric FoxP3-Fc(IgG) fusion construct/protein to effectively stimulate the immune responses against Treg cells. Materials and Methods: Previously constructed FoxP3-Fc(IgG) DNA vaccine and its protein counterpart were injected into C57BL/6 mice in a prime/boost regimen. After 2 weeks, the mice were killed to measure the frequency of Tregs in their spleens, as well as analyze their specific cytokine production, T-cell proliferation, and CD8(+) T-cell cytotoxicity against FoxP3 protein. Results: FACS analysis of FoxP3(+) CD4(+) cells in splenocytes revealed the efficiency of FoxP3(+) DNA-prime protein-boost strategy to decrease the Treg cells and further showed considerable superiority of Fc(IgG) fusion strategy. This significant reduction in Treg frequency was also concomitant with higher FoxP3-specific CTL and Th1 responses in FoxP3-Fc vaccinated animals. Conclusions: Prime/boost vaccination against FoxP3 in addition to enhanced antigen presentation by means of Fc fusion strategy could be successfully considered for Treg depletion studies. Validity of this approach should be experimentally tested in preclinical tumor models.
引用
收藏
页码:269 / 275
页数:7
相关论文
共 35 条
[1]   CD8+T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells [J].
Antony, PA ;
Piccirillo, CA ;
Akpinarli, A ;
Finkelstein, SE ;
Speiss, PJ ;
Surman, DR ;
Palmer, DC ;
Chan, CC ;
Klebanoff, CA ;
Overwijk, WW ;
Rosenberg, SA ;
Restifo, NP .
JOURNAL OF IMMUNOLOGY, 2005, 174 (05) :2591-2601
[2]   Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma [J].
Attia, P ;
Maker, AV ;
Haworth, LR ;
Rogers-Freezer, L ;
Rosenberg, SA .
JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) :582-592
[3]  
BERD D, 1988, CANCER RES, V48, P1671
[4]   Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949
[5]   Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials [J].
Curtin, James F. ;
Candolfi, Marianela ;
Fakhouri, Tamer M. ;
Liu, Chunyan ;
Alden, Anderson ;
Edwards, Matthew ;
Lowenstein, Pedro R. ;
Castro, Maria G. .
PLOS ONE, 2008, 3 (04)
[6]   Fc-fusion proteins: new developments and future perspectives [J].
Czajkowsky, Daniel M. ;
Hu, Jun ;
Shao, Zhifeng ;
Pleass, Richard J. .
EMBO MOLECULAR MEDICINE, 2012, 4 (10) :1015-1028
[7]   Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination [J].
Dorgham, Karim ;
Abadie, Valerie ;
Iga, Mutsunori ;
Hartley, Oliver ;
Gorochov, Guy ;
Combadiere, Behazine .
VACCINE, 2008, 26 (26) :3252-3260
[8]   CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model [J].
Espenschied, J ;
Lamont, J ;
Longmate, J ;
Pendas, S ;
Wang, ZD ;
Diamond, DJ ;
Ellenhorn, JDI .
JOURNAL OF IMMUNOLOGY, 2003, 170 (06) :3401-3407
[9]  
Flanagan Meg L, 2007, Methods Mol Biol, V378, P33, DOI 10.1007/978-1-59745-323-3_3
[10]   Foxp3 Programs the Development and Function of CD4+CD25+ Regulatory T Cells (Reprinted from vol 4, pg 330-336, 2003) [J].
Fontenot, Jason D. ;
Gavin, Marc A. ;
Rudensky, Alexander Y. .
JOURNAL OF IMMUNOLOGY, 2017, 198 (03) :986-992